title: [Chemotherapy in advanced transitional cell carcinoma of the urinary tract. Phase II trial of a combination of doxorubicin and cisplatin].
abstract: Between January 1, 1983 and December 31, 1984, 18 patients with advanced transitional cell carcinoma of the urothelium were treated in a Phase II trial with doxorubicin 45 mg/sqm plus cisplatin 90/mg/sqm/day every four weeks. 17 patients were evaluable for response. There were: 4 partial responses (24% of response objective effects, 95% confidence limits are 15% and 33%) and 13 failures. The median survival was 18.5 months for responders and 10 months for non responders.
authors.affiliation: Département de Médecine, Institut Gustave Roussy, Villejuif.
authors.forename: V
authors.initials: V
authors.lastname: Ribrag
authors.forename: M
authors.initials: M
authors.lastname: Ghnassia
authors.forename: C
authors.initials: C
authors.lastname: Théodore
authors.forename: M
authors.initials: M
authors.lastname: Ghosn
authors.forename: G
authors.initials: G
authors.lastname: Piot
authors.forename: D
authors.initials: D
authors.lastname: Beurton
authors.forename: J
authors.initials: J
authors.lastname: Cukier
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D004317:Doxorubicin; D002945:Cisplatin
vernacular_title: Chimiothérapie des stades avancés de carcinomes à cellules transitionnelles des voies urinaires. Essai phase II d'une association de doxorubicine et de cisplatine.